Published in World J Hepatol on July 28, 2016
(18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl (2006) 3.73
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl (2014) 3.11
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33
Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant (2008) 2.04
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl (2013) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl (2008) 1.68
Alphafetoprotein: an obituary. J Hepatol (2001) 1.68
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology (1984) 1.41
Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl (2015) 1.40
Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant (2009) 1.27
Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl (2010) 1.26
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut (2015) 1.16
Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol (2012) 1.12
Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis (2007) 1.11
Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2007) 1.10
Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation (2007) 1.10
Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl (2007) 1.09
Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology (2011) 1.08
Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer (2015) 1.07
Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05
Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant (2011) 1.00
Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol (2014) 0.98
Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology (2015) 0.97
Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol (2008) 0.96
Liver transplantation for hepatocellular carcinoma: role of biopsy. Liver Transpl (2007) 0.91
Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol (2015) 0.89
Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant (2011) 0.83
HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis (2007) 0.83
Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma. Transplantation (2015) 0.83
Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl (2007) 0.82
Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg (2014) 0.82
Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl (2008) 0.81
A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int (2016) 0.81
Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl (2015) 0.78